Has Daruka Mahadevan, MD received payments from drug or device companies?

Yes. Drug and device makers reported $18,972 in general payments to Daruka Mahadevan, MD across 42 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Daruka Mahadevan, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Daruka Mahadevan, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Daruka Mahadevan, MD

Medical Oncology · San Antonio, TXNPI 1841398302

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $15,190 of the $18,972 with a category attached, or 80.1%. 21 manufacturers reported payments, led by Janssen Research & Development, LLC at 53.9% of the total. Reporting peaked in 2022 at $6,367 and has fallen 95.0% since, to $321 in 2025.

$18,972in general payments, 2019–2025

Across 42 payments — averaging $451.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Janssen Research & Development, LLC$10K
Pfizer$4K
Histosonics, Inc.$1K
Otsuka Pharmaceutical Co., Ltd.$599
BD$460
ADC Therapeutics America, Inc.$221
plus $2K from 15 others

$3,094,934in research payments, 2019–2025

Across 577 payments — averaging $5363.84 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

AbbVie$1M
Pfizer$636K
Merck$581K
Beigene, Ltd.$432K
Genentech, Inc.$232K
Seagen Inc.$70K
plus $109K from 6 others

What the payments were for

Consulting fees$15,19080%
Speaking & faculty fees$5303%
Travel & lodging$8775%
Food & beverage$2,16011%
Education$2141%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Janssen Research & Development, LLC	7	$10,230
Pfizer	4	$4,436
Histosonics, Inc.	4	$1,089
Otsuka Pharmaceutical Co., Ltd.	3	$599
BD	1	$460
ADC Therapeutics America, Inc.	2	$221
Lilly USA, LLC	2	$214
TG Therapeutics, Inc.	2	$214
Tempus AI, Inc	1	$213
Sanofi	1	$200
Beigene USA, Inc.	2	$197
Deciphera Pharmaceuticals Inc.	1	$159
Sanofi-aventis U.S. LLC	2	$149
Ipsen Biopharmaceuticals, Inc	1	$141
Stemline Therapeutics Inc.	1	$117
Springworks Therapeutics, Inc.	1	$102
Pharmacosmos Therapeutics Inc.	1	$94
Amgen	3	$48
Takeda Pharmaceuticals U.S.A., Inc.	1	$35
Novartis	1	$28
Janssen Scientific Affairs, LLC	1	$25

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

DAURISMO$4,000
Tempus Pixel$213
CAPRELSA$200
QINLOCK$159
ONIVYDE$141
Orserdu$117
RETEVMO$115
JAYPIRCA$115
UKONIQ$104
OGSIVEO$102
ELITEK$100

How this compares

$18,972 in reported general payments places this provider in the 70th percentile of 495 medical oncology providers in Texas.

See all medical oncology providers in Texas →

Medicare billing

Part B allowed, 2024

$72,566

Medicare patients

Services billed

3,259

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
CabometyxCabozantinib S-Malate	12	$272,099
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen	23	$931
Prochlorperazine Maleate	18	$373
Levothyroxine Sodium	69	$319
Potassium Chloride	35	$236
Ondansetron OdtOndansetron	12	$229
Acetaminophen-CodeineAcetaminophen With Codeine	11	$137
Ondansetron Hcl	15	$119
Gabapentin	22	$56
Lorazepam	16	$46
Prednisone	15	$38

Paid to pharmacies, not to this prescriber.

Other medical oncology in San Antonio

Vijay GunugantiSan Antonio$1.5M
Virginia KaklamaniSan Antonio$787K
John SarantopoulosSan Antonio$588K
Sukeshi AroraSan Antonio$188K
Anthony TolcherSan Antonio$125K
Zohra NooruddinSan Antonio$113K
Moshe LevyDallas$5.1M
Suresh RatnamMcAllen$3M
Roy HerbstHouston$1.9M
Andrew WhiteleyDallas$1.7M

See the full list for Texas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →